This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

PharmAthene Presents New Anthrax Anti-Toxin Data At The ASM Biodefense And Emerging Diseases Research Meeting

ANNAPOLIS, Md., Feb. 8, 2011 /PRNewswire/ -- PharmAthene, Inc. (NYSE Amex: PIP), a biodefense company developing medical countermeasures against biological and chemical threats, announced today that new pharmacokinetic data from the Company's Valortim® anthrax anti-toxin program were presented at the 9th Annual ASM Biodefense and Emerging Diseases Research Meeting, held in Washington, DC, February 6-9, 2011.  The data were presented by Dr. Elizabeth Leffel, Director of Non-Clinical Sciences for PharmAthene, in a poster presentation entitled, "Pharmacokinetics of a Monoclonal Anthrax Anti-Toxin Antibody in Healthy and Infected Cynomolgus Macaques."

Valortim® is a fully human anti-toxin monoclonal antibody being developed by PharmAthene for the prevention and treatment of inhalational anthrax.  Valortim® was licensed from Medarex, which was acquired by Bristol-Myers Squibb in 2009.  Nonclinical animal studies suggest that Valortim® has the potential to provide protection against anthrax infection when administered prophylactically (prior to the emergence of symptoms of anthrax infection) and also may increase survival when administered therapeutically (once symptoms become evident).

"Anti-toxins such as Valortim® are an important part of our nation's biodefense armamentarium against anthrax," commented Dr. Thomas Fuerst, Executive Vice President and Chief Scientific Officer.  "The accumulating data suggest that Valortim® possesses important characteristics that may make it a strong choice for procurement in the Strategic National Stockpile, including: demonstrated efficacy in animal models as both a prophylactic and therapeutic for inhalational anthrax, efficacy at low doses, and a mechanism of action with unique properties that make it an attractive candidate.  We look forward to continuing to work collaboratively with the U.S. Government to develop innovative new biodefense countermeasures like Valortim® to protect our nation's citizens both at home and on the battlefield."

Valortim® Findings Reported

The objective of the study was to compare the pharmacokinetics (PK) of Valortim® following a single intravenous injection in non-challenged cynomolgus macaques (cynos) to that in cynos infected with Bacillus anthracis.  

In this study, 30 healthy non-challenged cynos were given 1, 5, 10, 20, or 40 mg/kg of Valortim® on Day 1.  Separately, 48 cynos were challenged with Bacillus anthracis spores and subsequently given 5, 10, 20, or 40 mg/kg of Valortim® at the time they were determined to be antigenemic (evidence of bacterial infection in the bloodstream).

Serum was collected over 56 days in the non-challenged animals and over 5 days in challenged animals for pharmacokinetics as measured by ELISA.  Non-compartmental analysis was conducted on the concentration-time profiles in all cynos.

1 of 2

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free
AAPL $93.09 -0.57%
FB $118.35 0.25%
GOOG $700.69 0.72%
TSLA $214.50 -3.60%
YHOO $37.11 3.10%


Chart of I:DJI
DOW 17,705.19 +53.93 0.31%
S&P 500 2,057.39 +6.27 0.31%
NASDAQ 4,738.7260 +13.0870 0.28%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs